Second Quarter 2017 Financial Highlights:
Total Q2 2017 revenues increased 60% to $3.6 million, which includes both product sales and grant income, up from $2.2 million in Q2 2016
Q2 2017 product sales were $3.0 million, an increase of 64% or $1.2 million, compared to $1.9 million in Q2 2016, driven by record unit sales
Product gross margins for Q2 2017 were approximately 65% in Q2 2017 as compared to 68% for Q2 2016, a result of the mix of direct and distributor sales
Trailing twelve-month product sales for the period ending June 30, 2017 were $10.4 million, compared to $6.0 million for the period ending June 30, 2016
As of June 30, 2017, the Company had $16.4 million in cash and cash equivalents, which is expected to provide sufficient working capital to fund our operations and clinical trials through 2018
Besser als erwartet, weiter gehts!